Sanofi’s multiple sclerosis drug Aubagio won final approval from the U.K.’s health-cost agency, allowing access to a market in which it will compete with Novartis AG’s Gilenya.
The National Institute for Health and Care Excellence, or NICE, recommended Aubagio, also known as teriflunomide, as a treatment option for adults with relapsing-remitting multiple sclerosis, the most common form of the disease, it said in a statement today. The decision confirms a preliminary ruling made last month in which NICE recommended the drug after Paris-based Sanofi agreed to a price cut......... Read More - http://www.ms-uk.org/aubagio
MS drug Aubagio wins final approval from NICE
MS drug Aubagio wins final approval from NICE
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post